Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

ALEXION PHARMACEUTICALS (ALXN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/10/2018 07/11/2018 07/12/2018 07/13/2018 07/16/2018 Date
131.91(c) 131.12(c) 134.29(c) 135.87(c) 134.58(c) Last
894 809 825 278 1 618 371 1 574 398 1 132 168 Volume
+0.25% -0.60% +2.42% +1.18% -0.95% Change
More quotes
Financials (USD)
Sales 2018 4 000 M
EBIT 2018 1 954 M
Net income 2018 482 M
Debt 2018 1 164 M
Yield 2018 -
Sales 2019 4 669 M
EBIT 2019 2 348 M
Net income 2019 1 370 M
Finance 2019 3 395 M
Yield 2019 -
P/E ratio 2018 54,87
P/E ratio 2019 21,56
EV / Sales2018 7,85x
EV / Sales2019 5,75x
Capitalization 30 231 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
07/26Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
07/10ALEXION PHARMACEUTICALS : Abingworth closes BioVentures VII fund at $315M
AQ
07/03ALEXION PHARMACEUTICALS : Submits Application for Approval of ALXN1210 as a Trea..
AQ
07/03ALEXION PHARMACEUTICALS : to Report Second Quarter 2018 Results on Thursday, Jul..
AQ
06/29ALEXION PHARMACEUTICALS INC : Change in Directors or Principal Officers (form 8-..
AQ
06/28ALEXION PHARMACEUTICALS : to Report Second Quarter 2018 Results on Thursday, Jul..
BU
06/28ALEXION PHARMACEUTICALS : Submits Application for Approval of ALXN1210 as a Trea..
BU
06/22ALEXION PHARMACEUTICALS : Submits Application For Priority Review And Approval O..
AQ
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19ALEXION PHARMACEUTICALS : Submits Application for Priority Review and Approval o..
BU
06/19SOLID BIOSCIENCES : FDA lifts clinical hold on Solid's DMD gene therapy
AQ
More news
Sector news : Biopharmaceuticals
09:05aInvestor 2Q Net Profit Rises 34%
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
07/16Startup Producing Cell-Grown Meat Raises New Funding
DJ
07/16J&J'S JANSSEN : Credence Trial of Invokana Being Stopped Early for Positive Effi..
DJ
07/16ASTRAZENECA : Swedish Business Appoints New CEO
DJ
More sector news : Biopharmaceuticals
Latest Tweets
07/16Alexion Pharmaceuticals $ALXN Stock Rating Upgraded by ValuEngine  
07/15Paul J. Clancy Sells 5,241 Shares of Alexion Pharmaceuticals, Inc. $ALXN Stoc.. 
07/15ValuEngine Upgrades Alexion Pharmaceuticals $ALXN to Hold  
07/14$ALXN is Bullish above $135.04. Trade near $135.04  
07/14Trading Ideas: Alexion (AXLN): new entry long ? FREE trade-of-week via ?
3
More tweets
Qtime:138
News from SeekingAlpha
07/09Achillion Pharmaceuticals - Biotech Gold For The Price Of Dirt 
06/303 THINGS IN BIOTECH, JUNE 30 : Aptose Gets Rolling Again; Tesaro Heads To China;.. 
06/21YOUR DAILY PHARMA SCOOP : Anika Fails Trial, Kala's Upcoming Catalyst, Sarepta S.. 
06/19Alexion files U.S. marketing application for ALXN1210 for PNH 
06/18A Review Of Adeno-Associated Virus Mediated Gene Therapies And A Closer Look .. 
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Technical analysis trends ALEXION PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 159 $
Spread / Average Target 18%
EPS Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Paul J. Clancy Chief Financial Officer & Executive Vice President
John J. Orloff Executive VP & Head-Research & Development
Andreas Rummelt Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS12.53%30 231
BIOGEN10.82%73 532
CSL LIMITED40.58%66 707
GRIFOLS4.81%18 391
BIOMARIN PHARMACEUTICAL15.21%18 309
WUXI BIOLOGICS CAYMAN INC--.--%12 855